 Killer Cells, Natural
"Killer Cells, Natural" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
| Descriptor ID |
D007694
|
| MeSH Number(s) |
A11.118.637.555.567.537 A15.145.229.637.555.567.537 A15.382.490.555.567.537
|
| Concept/Terms |
Killer Cells, Natural- Killer Cells, Natural
- Natural Killer Cells
- Cell, Natural Killer
- Cells, Natural Killer
- Killer Cell, Natural
- Natural Killer Cell
- NK Cells
- Cell, NK
- Cells, NK
- NK Cell
|
Below are MeSH descriptors whose meaning is more general than "Killer Cells, Natural".
Below are MeSH descriptors whose meaning is more specific than "Killer Cells, Natural".
This graph shows the total number of publications written about "Killer Cells, Natural" by people in UAMS Profiles by year, and whether "Killer Cells, Natural" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 2 | 0 | 2 | | 2018 | 2 | 1 | 3 | | 2017 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2015 | 3 | 0 | 3 | | 2014 | 2 | 1 | 3 | | 2013 | 0 | 1 | 1 | | 2012 | 4 | 1 | 5 | | 2011 | 3 | 1 | 4 | | 2010 | 2 | 2 | 4 | | 2009 | 0 | 1 | 1 | | 2008 | 2 | 1 | 3 | | 2007 | 2 | 0 | 2 | | 2006 | 1 | 1 | 2 | | 2005 | 1 | 1 | 2 | | 2004 | 1 | 0 | 1 | | 2003 | 1 | 3 | 4 | | 2002 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 1999 | 2 | 1 | 3 | | 1998 | 1 | 2 | 3 | | 1996 | 1 | 1 | 2 | | 1994 | 1 | 0 | 1 | | 1991 | 0 | 2 | 2 | | 1990 | 1 | 1 | 2 | | 1989 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Killer Cells, Natural" by people in Profiles over the past ten years.
-
Nakao T, Inomata T, Blanco T, Musayeva A, Tahvildari M, Amouzegar A, Yin J, Chauhan SK, Chen Y, Dana R. Amplified Natural Killer Cell Activity and Attenuated Regulatory T-cell Function Are Determinants for Corneal Alloimmunity in Very Young Mice. Transplantation. 2023 06 01; 107(6):1302-1310.
-
Zhang M, Acklin S, Gillenwater J, Du W, Patra M, Yu H, Xu B, Yu J, Xia F. SIRT2 promotes murine melanoma progression through natural killer cell inhibition. Sci Rep. 2021 06 21; 11(1):12988.
-
Casneuf T, Adams HC, van de Donk NWCJ, Abraham Y, Bald J, Vanhoof G, Van der Borght K, Smets T, Foulk B, Nielsen KC, Rusbuldt J, Axel A, Lysaght A, Ceulemans H, Stevenaert F, Usmani SZ, Plesner T, Avet-Loiseau H, Nijhof I, Mutis T, Schecter JM, Chiu C, Bahlis NJ. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2021 02; 35(2):573-584.
-
Pai RL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, Pierson SK, Powers V, Layman AAK, Kao C, Hakonarson H, van Rhee F, Betts MR, Kambayashi T, Fajgenbaum DC. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight. 2020 05 07; 5(9).
-
Adams HC, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry A. 2019 03; 95(3):279-289.
-
Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Turner M, Slaughter D, Friend R, Atrash S, Symanowski JT, Avalos BR, Copelan EA, Voorhees PM, Usmani SZ. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma. Biol Blood Marrow Transplant. 2019 03; 25(3):459-465.
-
Al-Attar A, Presnell SR, Clasey JL, Long DE, Walton RG, Sexton M, Starr ME, Kern PA, Peterson CA, Lutz CT. Human Body Composition and Immunity: Visceral Adipose Tissue Produces IL-15 and Muscle Strength Inversely Correlates with NK Cell Function in Elderly Humans. Front Immunol. 2018; 9:440.
-
Naglak EK, Morrison SG, Morrison RP. Neutrophils Are Central to Antibody-Mediated Protection against Genital Chlamydia. Infect Immun. 2017 10; 85(10).
-
Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, Johannesen HH, Becker JC, Pedersen KS, Dethlefsen C, Nielsen J, Gehl J, Pedersen BK, Thor Straten P, Hojman P. Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. Cell Metab. 2016 Mar 08; 23(3):554-62.
-
Maltez VI, Tubbs AL, Cook KD, Aachoui Y, Falcone EL, Holland SM, Whitmire JK, Miao EA. Inflammasomes Coordinate Pyroptosis and Natural Killer Cell Cytotoxicity to Clear Infection by a Ubiquitous Environmental Bacterium. Immunity. 2015 Nov 17; 43(5):987-97.
-
Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, Han Y, Wu H, Meng X, Xu H, Zhan F, Wu X, Shi J. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015 Sep 29; 6(29):26982-94.
-
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36.
-
Tosic V, Thomas DL, Kranz DM, Liu J, McFadden G, Shisler JL, MacNeill AL, Roy EJ. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity. PLoS One. 2014; 9(10):e109801.
-
Gao M, Gao L, Yang G, Tao Y, Hou J, Xu H, Hu X, Han Y, Zhang Q, Zhan F, Wu X, Shi J. Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism. Acta Biochim Biophys Sin (Shanghai). 2014 Jul; 46(7):597-604.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|